About QurAlis
QurAlis is a company based in Cambridge (United States) founded in 2016 by Clifford J Woolf and Kasper Roet. QurAlis has raised $155.45 million across 7 funding rounds from investors including Amgen, EQT and HHS. The company has 38 employees as of December 31, 2022. QurAlis offers products and services including FlexASO® Platform and QRL-101. QurAlis operates in a competitive market with competitors including Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
- Headquarter Cambridge, United States
- Employees 38 as on 31 Dec, 2022
- Founders Clifford J Woolf, Kasper Roet
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Quralis Corporation
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$155.45 M (USD)
in 7 rounds
-
Latest Funding Round
$19.95 M (USD), Series B
Aug 21, 2025
-
Investors
Amgen
& 18 more
-
Employee Count
38
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of QurAlis
QurAlis offers a comprehensive portfolio of products and services, including FlexASO® Platform and QRL-101.
Proprietary platform for anti-sense oligonucleotide therapies
Therapy targeting Kv7 for ALS treatment
People of QurAlis
Unlock access to complete
Unlock access to complete
Funding Insights of QurAlis
QurAlis has successfully raised a total of $155.45M across 7 strategic funding rounds. The most recent funding activity was a Series B round of $19.95 million completed in August 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in QurAlis
QurAlis has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Amgen, EQT and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
EQT is recognized as a global investment organization focused on value creation.
|
Locked | Locked | Locked | |
|
Private equity investments in life sciences businesses are managed.
|
Locked | Locked | Locked | |
|
Life-Sciences focused Early stage Corporate VC Firm investing in the US
|
Locked | Locked | Locked |
Investor details for QurAlis
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by QurAlis
Investment portfolio details for QurAlis
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - QurAlis
Detailed financials for QurAlis
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Quralis Comparisons
Peer comparison for QurAlis
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of QurAlis
QurAlis operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, BridgeBio, ATAI, Forge Biologics and Spark Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases are developed to treat patients.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
Provider of cell therapies to treat cancer and hematologic conditions
|
Detailed competitors of QurAlis
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Quralis
Complete news archive for QurAlis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about QurAlis
QurAlis was founded in 2016 and raised its 1st funding round 2 years after it was founded.
QurAlis is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Kasper Roet is the current CEO of QurAlis. They have also founded this company.
QurAlis is a funded company, having raised a total of $155.45M across 7 funding rounds to date.
As of Dec 31, 2022, the latest employee count at QurAlis is 38.
QurAlis is engaged in discovering and developing new therapies for amyotrophic lateral sclerosis (ALS), which is a common form of motor neuron disease. The company has developed Optopatch technology which helps in stimulating the neurons and notes their electrical behavior. Their proprietary method clears toxic proteins and transcranial magnetic stimulation helps in diagnosing ALS by identifying biomarkers such as protein in the blood. In addition, other therapeutic targets like nerve threshold tracking, proteins in the cerebral spinal fluid helps to predict ALS. The company has a preclinical-stage program for ALS drugs targeting the Kv7.27.3 channel CSF cartridge device to remove DPR proteins.
QurAlis's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
QurAlis offers FlexASO® Platform and QRL-101.
QurAlis has 19 investors. Key investors include Amgen, EQT, HHS, Life Sciences Partners, and Viva BioInnovator.